UQ1
uniQure N.V
Save
–
Market cap
–
Current P/E
29.85x
Forward P/E
About
Health care
Sector
Biotechnology
Industry
uniQure N. V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B.
Similar securities
Based on sector and market capitalization
Report issue